IMMUNOPHARMACOLOGICAL STRATEGIES FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES

Authors

  • Lukas F. Schneider Department of Immunopharmacology Heidelberg Institute for Biomedical Research, Germany

Keywords:

immunopharmacology; autoimmune disease; inflammation; biologics; JAK inhibitors; cytokines; regulatory T cells; complement; precision medicine.

Abstract

Autoimmune and chronic inflammatory diseases arise from sustained dysregulation of innate and adaptive immune pathways, loss of self-tolerance, and persistent cytokine-mediated tissue injury. Modern immunopharmacology has shifted treatment from broad immunosuppression toward mechanism-based modulation of selected immune pathways. This structured review evaluates established and emerging pharmacological strategies used in rheumatoid arthritis, inflammatory bowel disease, psoriasis, systemic lupus erythematosus, vasculitis, multiple sclerosis and related immune-mediated disorders. A literature synthesis was performed using contemporary international reviews and translational studies focusing on cytokine blockade, Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibition, B-cell and T-cell directed therapy, complement inhibition, regulatory T-cell manipulation, antigen-specific tolerance, immunoengineering and chimeric antigen receptor (CAR) T-cell approaches. The evidence indicates that TNF, IL-6, IL-17/IL-23 and JAK-STAT targeting can produce rapid and clinically meaningful control of inflammation in selected diseases, while B-cell and complement-directed therapies provide particular benefit when humoral immunity or complement activation is central to pathogenesis. Newer strategies aim not merely to suppress inflammation but to restore durable immune tolerance. The principal limitations remain infection risk, heterogeneous treatment response, high cost, secondary loss of efficacy and incomplete biomarkers for patient selection. Future immunopharmacology is therefore expected to integrate molecular phenotyping, tissue-level biomarkers and adaptive treatment algorithms to achieve more precise and safer immune modulation.

References

1.Ramirez-Valle, F., Maranville, J. C., Roy, S., et al. (2024). Sequential immunotherapy: towards cures for autoimmunity. Nature Reviews Drug Discovery, 23, 501-524.

2.Szekanecz, Z., Buch, M. H., Charles-Schoeman, C., et al. (2024). Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nature Reviews Rheumatology, 20, 101-115.

3.Neurath, M. F. (2024). Strategies for targeting cytokines in inflammatory bowel disease. Nature Reviews Immunology, 24, 559-576.

4.Morand, E., Merola, J. F., Tanaka, Y., Gladman, D., & Fleischmann, R. (2024). TYK2: an emerging therapeutic target in rheumatic disease. Nature Reviews Rheumatology, 20, 232-240.

5.Sumida, T. S., Cheru, N. T., & Hafler, D. A. (2024). The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases. Nature Reviews Immunology, 24, 503-517.

6.McBride, D. A., Jones, R. M., Bottini, N., & Shah, N. J. (2024). The therapeutic potential of immunoengineering for systemic autoimmunity. Nature Reviews Rheumatology, 20, 203-215.

7.Mougiakakos, D., et al. (2024). Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nature Reviews Rheumatology, 20, 531-544.

8.Leonard, W. J., & Lin, J.-X. (2023). Strategies to therapeutically modulate cytokine action. Nature Reviews Drug Discovery, 22, 827-854.

9.Mastellos, D. C., Hajishengallis, G., & Lambris, J. D. (2024). A guide to complement biology, pathology and therapeutic opportunity. Nature Reviews Immunology, 24, 118-141.

10.Becher, B., Derfuss, T., & Liblau, R. (2024). Targeting cytokine networks in neuroinflammatory diseases. Nature Reviews Drug Discovery, 23, 862-879.

11.Wardell, C. M., Boardman, D. A., & Levings, M. K. (2025). Harnessing the biology of regulatory T cells to treat disease. Nature Reviews Drug Discovery, 24, 93-111.

12.Buckner, J. H. (2025). Antigen-specific immunotherapies for autoimmune disease. Nature Reviews Rheumatology, 21, 88-97.

13.Croft, M., Salek-Ardakani, S., & Ware, C. F. (2024). Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer. Nature Reviews Drug Discovery, 23, 939-961.

14.Castelo-Soccio, L., Kim, H., Gadina, M., Schwartzberg, P. L., Laurence, A., & O'Shea, J. J. (2023). Protein kinases: drug targets for immunological disorders. Nature Reviews Immunology, 23, 787-806.

15.Holers, V. M. (2023). Complement therapeutics are coming of age in rheumatology. Nature Reviews Rheumatology, 19, 470-485.

Published

2026-09-23